Literature DB >> 15912425

Two C-methyl derivatives of [11C]WAY-100635--effects of an amido alpha-methyl group on metabolism and brain 5-HT1A receptor radioligand behavior in monkey.

Julie A McCarron1, Sandrine Marchais-Oberwinkler, Victor W Pike, Jari Tarkiainen, Christer Halldin, Judit Sóvagó, Balàzs Gulyas, Hakan V Wikström, Lars Farde.   

Abstract

PURPOSE: [carbonyl-11C]N-(2-(1-(4-(2-methoxyphenyl)-piperazinyl)ethyl)-N-pyridinyl)cyclohexanecarboxamide ([carbonyl-11C]WAY-100635) is an effective radioligand for imaging brain 5-HT1A receptors with positron emission tomography (PET). However, this radioligand has some drawbacks for deriving relative regional receptor densities, including rapid metabolism, which acts against accurate definition of an arterial input function for compartmental modeling, and very low nonspecific binding in brain, which detracts from the accuracy of modeling by a simplified reference tissue (cerebellum) approach. Here, in a search for a radioligand that overcomes these limitations, we investigated the effects of introducing a single methyl group at either of the carbon atoms alpha to the amide bond in [11C]WAY-100635. PROCEDURES: Ligands with a methyl group on the alpha carbon of the cyclohexyl group (SWAY) or the alpha carbon of the C2H4 linker ((R,S)-JWAY) were synthesized and tested for binding affinity and intrinsic activity at 5-HT1A receptors. SWAY was labeled with carbon-11 (t1/2 = 20.4 minutes; beta+ = 99.8%) in its O-methyl group and (R,S)-JWAY in its carbonyl group. Each radioligand was evaluated by PET experiments in cynomolgus monkey.
RESULTS: SWAY and (R,S)-JWAY were found to be high-affinity antagonists at 5-HT1A receptors. After injection of [11C]SWAY into monkey, radioactivity uptake in brain reached a maximum of 3% at 4.5 minutes and decreased to 0.7% at 72 minutes. However, over the time span of the experiment, radioactivity concentrations in 5-HT1A receptor-rich brain regions were only fractionally higher than in cerebellum. Radioactivity represented by parent radioligand in plasma was 39% at 45 minutes. After injection of [11C](R,S)-JWAY alone, radioactivity uptake in brain reached a maximum of 4.8% at 2.5 minutes and decreased to 1.2% at 90 minutes. At this time, radioactivity concentration in 5-HT1A receptor-rich brain regions was markedly greater than in cerebellum. In another PET experiment, the monkey was predosed with WAY-100635 before [11C](R,S)-JWAY injection. At 90 minutes after injection, the ratio of radioactivity in 5-HT1A receptor-rich regions to that in cerebellum was reduced to near unity. Radioactivity represented by parent radioligand in plasma was 12% at 45 minutes.
CONCLUSIONS: [11C](R,S)-JWAY, but not [11C]SWAY, gives a sizeable 5-HT1A receptor-selective PET signal in monkey. The presence of a C-methyl group adjacent to the amide bond in SWAY or (R,S)-JWAY fails to counter metabolism.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15912425     DOI: 10.1007/s11307-005-4127-5

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  25 in total

1.  Quantitative analysis of [carbonyl-(11)C]WAY-100635 PET studies.

Authors:  R N Gunn; A A Lammertsma; P M Grasby
Journal:  Nucl Med Biol       Date:  2000-07       Impact factor: 2.408

2.  Quantification of [Carbonyl-(11)C]WAY-100635 binding: considerations on the cerebellum.

Authors:  V Oikonen; T Allonen; K Någren; J Kajander; J Hietala
Journal:  Nucl Med Biol       Date:  2000-07       Impact factor: 2.408

3.  Interaction of alpha-chymotrypsin with several alpha-methyl-alpha-acylamino acid methyl esters.

Authors:  H R ALMOND; D T MANNING; C NIEMANN
Journal:  Biochemistry       Date:  1962-03       Impact factor: 3.162

4.  [carbonyl-11C]Desmethyl-WAY-100635 (DWAY) is a potent and selective radioligand for central 5-HT1A receptors in vitro and in vivo.

Authors:  V W Pike; C Halldin; J A McCarron; C Lundkvist; E Hirani; H Olsson; S P Hume; P Karlsson; S Osman; C G Swahn; H Hall; H Wikström; M Mensonidas; K G Poole; L Farde
Journal:  Eur J Nucl Med       Date:  1998-04

5.  Characterization of the radioactive metabolites of the 5-HT1A receptor radioligand, [O-methyl-11C]WAY-100635, in monkey and human plasma by HPLC: comparison of the behaviour of an identified radioactive metabolite with parent radioligand in monkey using PET.

Authors:  S Osman; C Lundkvist; V W Pike; C Halldin; J A McCarron; C G Swahn; N Ginovart; S K Luthra; C J Bench; P M Grasby; H Wikström; T Barf; I A Cliffe; A Fletcher; L Farde
Journal:  Nucl Med Biol       Date:  1996-07       Impact factor: 2.408

Review 6.  Visualisation of serotonin-1A (5-HT1A) receptors in the central nervous system.

Authors:  J Passchier; A van Waarde
Journal:  Eur J Nucl Med       Date:  2001-01

7.  The ECAT EXACT HR: performance of a new high resolution positron scanner.

Authors:  K Wienhard; M Dahlbom; L Eriksson; C Michel; T Bruckbauer; U Pietrzyk; W D Heiss
Journal:  J Comput Assist Tomogr       Date:  1994 Jan-Feb       Impact factor: 1.826

8.  New halogenated [11C]WAY analogues, [11C]6FPWAY and [11C]6BPWAY--radiosynthesis and assessment as radioligands for the study of brain 5-HT1A receptors in living monkey.

Authors:  J Sandell; C Halldin; V W Pike; Y H Chou; K Varnäs; H Hall; S Marchais; B Nowicki; H V Wikström; C G Swahn; L Farde
Journal:  Nucl Med Biol       Date:  2001-02       Impact factor: 2.408

9.  Quantitative analyses of carbonyl-carbon-11-WAY-100635 binding to central 5-hydroxytryptamine-1A receptors in man.

Authors:  L Farde; H Ito; C G Swahn; V W Pike; C Halldin
Journal:  J Nucl Med       Date:  1998-11       Impact factor: 10.057

10.  Characterisation of the appearance of radioactive metabolites in monkey and human plasma from the 5-HT1A receptor radioligand, [carbonyl-11C]WAY-100635--explanation of high signal contrast in PET and an aid to biomathematical modelling.

Authors:  S Osman; C Lundkvist; V W Pike; C Halldin; J A McCarron; C G Swahn; L Farde; N Ginovart; S K Luthra; R N Gunn; C J Bench; P A Sargent; P M Grasby
Journal:  Nucl Med Biol       Date:  1998-04       Impact factor: 2.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.